<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998972</url>
  </required_header>
  <id_info>
    <org_study_id>NAC-CHUN1</org_study_id>
    <nct_id>NCT00998972</nct_id>
  </id_info>
  <brief_title>N-acetyl-cysteine (NAC) and Kidney Graft Function</brief_title>
  <official_title>Preventive Administration of N-acetyl-cysteine (NAC) in Organ Donor: Effects on Kidney Graft Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Anesthesiologie des Alpes Maritimes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut d'Anesthesiologie des Alpes Maritimes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the effect of N-acetyl-cysteine (NAC) administration in&#xD;
      organ donors on the kidney graft function of recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemia-reperfusion is a major contributing factor for delayed renal function after&#xD;
      transplantation. It has been shown that the administration of an antioxidant, i.e. NAC, in&#xD;
      patients with chronic renal insufficiency may prevent radio contrast-induced nephropathy. Due&#xD;
      to its antioxidant effects, organ donor pretreatment with NAC has demonstrated to improve&#xD;
      renal graft function in two experimental studies. Study objectives: to compare the incidence&#xD;
      of delayed graft renal function between two groups of patients, i.e., those receiving the&#xD;
      graft from organ donors pretreated with NAC and a group control. The primary endpoint was the&#xD;
      number of delayed graft function defined as the requirement of at least one sequence of&#xD;
      dialysis during the first seven days following transplantation. Secondary endpoints:&#xD;
      evolution of creatininemia, azotemia at day 1, 7, 14 and ,30 after surgery; acute and delayed&#xD;
      transplant rejection; intrahospital mortality.&#xD;
&#xD;
      Patients inclusion: all organ donors and recipients were eligible Exclusion criteria: for&#xD;
      organ donors were preexistent chronic renal insufficiency and contra-indications for kidney&#xD;
      procurement; for recipient were transplantation outside our hospital The donors were&#xD;
      randomized in a single-blind fashion into two groups : the control group and the group&#xD;
      receiving 600 mg IV of NAC 1 hour before and 600 mg IV 2 hours after cerebral arteriography&#xD;
      required to diagnose brain death. Sample size has been calculated delayed graft function by&#xD;
      50% leading to include 118 recipients in each group.&#xD;
&#xD;
      Follow up: one year after transplantation. Study beginning in september 2006. Length of&#xD;
      inclusion during 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of delayed graft function</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of creatininemia and azotemia during the first month after transplantation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrahospital mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and delayed graft rejection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Brain Death</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control arm without any specific intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>600 mg intravenous before and 2 hours after cerebral arteriography</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>n-acetylcysteine administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all recipient for kidney graft in our hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  transplantation out side our hospital&#xD;
&#xD;
          -  refusal from the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole R Ichai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Reanimation Medicochirurgical. CHU de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>NICE cedex 01</city>
        <state>Alpes Maritimes</state>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>October 17, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <last_update_submitted>July 9, 2011</last_update_submitted>
  <last_update_submitted_qc>July 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carole Ichai</name_title>
    <organization>Institut d'Anesth√©siologie des AM</organization>
  </responsible_party>
  <keyword>kidney graft,</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

